Immix Biopharma Inc IMMX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
-
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
-
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
-
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
-
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
-
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Trading Information
- Previous Close Price
- $8.35
- Day Range
- $7.88–8.89
- 52-Week Range
- $2.85–15.10
- Bid/Ask
- $7.87 / $8.84
- Shares Outstanding
- 82.90M
- Market Cap
- $675.66M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 21
- Website
- https://www.immixbio.com
Valuation
|
Metric
|
IMMX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.54 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
IMMX
Financial Strength
|
Metric
|
IMMX
|
|---|---|
Quick Ratio | 24.95 |
Current Ratio | 25.13 |
Interest Coverage | — |
Quick Ratio
IMMX
Profitability
|
Metric
|
IMMX
|
|---|---|
Return on Assets (Normalized) | −39.82% |
Return on Equity (Normalized) | −45.08% |
Return on Invested Capital (Normalized) | −46.32% |
Return on Assets
IMMX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|X#q#!! | LOCK|kbvx! | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Z&j^L&# | LOCK|Twf@g | $83B | |||
| Moderna Inc
MRNA
| LOCK|&SYS^? | LOCK|bz | $80B | |||
| argenx SE ADR
ARGX
| LOCK|s%tn?q | LOCK|Tjw | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@bB>>dL | LOCK|?$# | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|m!#zR#y | LOCK|d>@< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#@X<x@JJ | LOCK|Byzj> | $28B | |||
| Incyte Corp
INCY
| LOCK|<#>!mWt | LOCK|XXt | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|SwFXrP | LOCK|m>G | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|p$&?K@ | LOCK|S@ | $14B |
United States